Development and in vitro evaluation of magnetic/hybrid nanostructured lipid carriers as a tool for targeted delivery of anticancer drugs

RODENAK-KLADNIEW B; NOACCO, NEHUEN; DE VERTI IP; CRESPO R; CASTRO GR; ISLAN GA; LEON IE

Mar del Plata

Congreso; REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019; 2019

Las Sociedades Argentinas de Investigación Clínica (SAIC), de Farmacología Experimental (SAFE), de Biología (SAB), de Protozoología (SAP), de Nanomedicinas (NANOMEDar) la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio (AACYTAL)

Cancer is the second cause of death in the world andmany of the current therapies are still ineffective or present highly toxic side effects.Nanostructured lipid carriers (NLC)are nanosized colloidal drug-delivery systems composed of a binary mixture of solid/ and liquid lipids coreand functionalizable surface developed for the encapsulation of lipophilic compounds in order to improve the stability, bioavailability, controlled release and selective targeting of therapeutic drugs. Here, we designed biocompatible hybrid chitosan (Chi) coated NLC containing the monoterpene 1,8-cineole (CN),acting as both bioactive molecule and nanostructuringliquid lipid, and magnetic nanoparticles (MNP), as a novel smartsystem for drug delivery to cancer cells.NLC, NLC/Chi and NLC/Chi/MNPnanoparticles (NPs) were prepared by ultrasonication. NPs were characterized by determining particle size,surface charge (SC), magnetic behavior,encapsulation efficiency (EE) and kinetic release of CN. Cell viability and cellular uptake of NPs were evaluated in human liver (HepG2) and lung (A549) cancercells,and normal lung (WI-38) cells.NPspresented spherical shape, sizes in the range of 190-270 nm with narrow distribution, and SC of -2.0 mV (NLC), +7.0 mV (NLC/Chi) y +10.0 mV (NLC/Chi/MNP). MNP and NLC/Chi/MNP showedmagnetic response with saturation moments of 79 and 60 emu/g Fe, respectively. The EE of CN forin all NPs was greater than 7790% and theyCN showedbiphasic CN release profile.CN-loaded NPsinhibitedup to 73.6%(A549) and 77.2% (HepG2) cancer cellsviability (p